Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Doxorubicin liposome
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Dragon Boat Training
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Drug-coated balloon angioplasty
The First People's Hospital of Lianyungang
Vertebral Artery Stenosis
1 trial -
EGFR Antibody
The First People's Hospital of Lianyungang
Nasopharyngeal Cancinoma (NPC)
1 trial -
EXENATIDE
Disc Medicine
paragangliomas
1 trial -
Edaravone Dexborneol
The First People's Hospital of Lianyungang
Stroke, Ischemic
1 trial -
Ejiao compound
The First People's Hospital of Lianyungang
Postpartum Anemia
1 trial -
Endostar
The First People's Hospital of Lianyungang
Brain Metastases
1 trial -
Endostar
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
Endostatins
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial -
Ensartinib
The First People's Hospital of Lianyungang
Solid Tumors
1 trial -
Envafolimab
The First People's Hospital of Lianyungang
Metastatic Colorectal Cancer
1 trial -
Envafolimab
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Envafolimab Injection
The First People's Hospital of Lianyungang
Gastrointestinal Neoplasms
1 trial -
Etoposide
The First People's Hospital of Lianyungang
Small Cell Lung Cancer Limited Stage
1 trial -
Experimental
The First People's Hospital of Lianyungang
Locally Advanced Rectal Cancer (LARC)
1 trial -
Experimental: tislelizumab+anlotinib
The First People's Hospital of Lianyungang
Thymic Carcinoma
1 trial -
FCN-437c+Fulvestrant
The First People's Hospital of Lianyungang
Breast Neoplasms
1 trial -
First-line Cohort
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma (HCC)
1 trial -
Fluoxetine
The First People's Hospital of Lianyungang
Depression
1 trial -
Fluoxetine (drug)
The First People's Hospital of Lianyungang
Hepatobiliary Malignancy
1 trial -
Furmonertinib
The First People's Hospital of Lianyungang
Non-Small Cell Lung Cancer
1 trial -
GVA + HDAC Consolidation & Gilteritinib Maintenance
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Ganoderma lucidum spore
The First People's Hospital of Lianyungang
Carcinoma, Non-Small-Cell Lung
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources